ArticlePloS one2026
Impact of demographic factors and HIV status on Hepatitis B vaccination adherence and completion rate among high-risk populations in Lagos State, Nigeria.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evaluation of hepatitis B vaccine effectiveness among fully vaccinated healthcare workers in Ethiopia.BMC infectious diseases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis-B-Virus (HBV) remains an important global public health concern, as well as a primary cause of both acute and chronic liver diseases, with over 18 million people infected by the virus in Nigeria. This study evaluated the impact of HIV status, age, and gender of high-risk populations on HBV vaccination adherence and completion rate in Lagos state, Nigeria. A retrospective study design was utilized to access the clinic data of 641 study participants who participated in the HBV program at the one-stop-shop clinic between June 2021 to June 2024. Data on age, HIV status, gender, population type, and the date of each dose of administered vaccine were recorded. To estimate the odds-ratios (ORs) and adjusted-ORs at 95% confidence intervals (CIs), bivariate/multivariate logistic regression models were utilized, and the association between age, gender, HIV status, and HBV vaccination adherence and the completion rate was examined. The study participants had a mean age of 21.7 ± 8.8 years and were composed of 510 (79.6%) males, 131 (20.4%) females; 162 (25.3%) participants living with HIV, 423 (66.0%) HIV-negative participants, 500 (78.0%) MSM, and 115 (17.9%) FSW. The overall vaccination completion rate was 45.4%, with significant variation by age group (p = 0.004). The highest completion rates were observed among participants aged 30-34 years (58.4%) and 35-39 years (57.8%), while younger participants aged 15-29 had lower adherence. Gender and HIV status were not independently associated with vaccination completion (p > 0.05). Age was the only factor significantly affecting completion (AOR: 1.92, 95% CI: 1.23, 3.03). HBV vaccination coverage in high-risk populations is low in Lagos State. This suggests that the HBV vaccination program in the state is still facing significant challenges. Creating awareness about HBV infection and strengthening the availability, accessibility, and cost effectiveness of HBV service uptake will enhance the program's success.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.